UK govt and Bill & Melinda Gates Foundation announce £3 billion malaria fund

26 January 2016
vaccinebig

George Osborne, UK Chancellor of the Exchequer, and Bill Gates, co-chairman of the Bill & Melinda Gates Foundation, have announced a funding of £3 billion ($4.28 billion) over the next five years to aid research and other efforts to eliminate malaria in the UK.

The initiative has been welcomed by Global Fund, a partnership between governments, civil society, the private sector designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics.

The new fund will accelerate gains made against the mosquito-borne disease. Global efforts have already achieved a 60% decline in deaths since 2000, when malaria killed one million people, mostly young children. The announcement underscores the need to expand efforts to eliminate this preventable disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical